Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation

被引:132
作者
Anderson, K
Jacobson, JS
Heitjan, DF
Zivin, JG
Hershman, D
Neugut, AI
Grann, VR
机构
[1] Columbia Univ, Joseph L Mailman Sch Publ Hlth, Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY 10032 USA
[2] New York Presbyterian Hosp, New York, NY USA
[3] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
关键词
D O I
10.7326/0003-4819-144-6-200603210-00006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: For BRCA1 or BRCA2 mutation carriers, decision analysis indicates that prophylactic surgery or chemoprevention leads to better survival than surveillance alone. Objective: To evaluate the cost-effectiveness of the preventive strategies that are available to unaffected women carrying a single BRCA1 or BRCA2 mutation with high cancer penetrance. Design: Markov modeling with Monte Carlo simulations and probabilistic sensitivity analyses. Data Sources: Breast and ovarian cancer incidence and mortality rates, preference ratings, and costs derived from the literature; the Surveillance, Epidemiology, and End Results (SEER) Program; and the Health Care Financing Administration (now the Centers for Medicare & Medicaid Services). Target Population: Unaffected carriers of a single BRCA1 or BRCA2 mutation 35 to 50 years of age. Time Horizon: Lifetime. Perspective: Health policy, societal. Interventions: Tamoxifen, oral contraceptives, bilateral salpingo-oophorectomy, mastectomy, both surgeries, or surveillance. Outcome Measures: Cost-effectiveness. Results of Base-Case Analysis: For mutation carriers 35 years of age, both surgeries (prophylactic bilateral mastectomy and oophorectomy) had an incremental cost-effectiveness ratio over oophorectomy alone of $2352 per life-year for BRCA1 and $100 per life-year for BRCA2. With quality adjustment, oophorectomy dominated all other strategies for BRCA1 and had an incremental cost-effectiveness ratio of $2281 per life-year for BRCA2. Results of Sensitivity Analysis: Older age at intervention increased the cost-effectiveness of prophylactic mastectomy for BRCA1 mutation carriers to $73 755 per life-year. Varying the penetrance, mortality rates, costs, discount rates, and preferences had minimal effects on outcomes. Limitations: Results are dependent on the accuracy of model assumptions. Conclusion: On the basis of this model, the most cost-effective strategies for BRCA mutation carriers, with and without quality adjustment, were oophorectomy alone and oophorectomy and mastectomy, respectively.
引用
收藏
页码:397 / 406
页数:10
相关论文
共 70 条
[1]   Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations:: a combined analysis of 22 population based studies [J].
Antoniou, AC ;
Pharoah, PDP ;
Narod, S ;
Risch, HA ;
Eyfjord, JE ;
Hopper, JL ;
Olsson, H ;
Johannsson, O ;
Borg, Å ;
Pasini, B ;
Radice, P ;
Manoukian, S ;
Eccles, DM ;
Tang, N ;
Olah, E ;
Anton-Culver, H ;
Warner, E ;
Lubinski, J ;
Gronwald, J ;
Gorski, B ;
Tulinius, H ;
Thorlacius, S ;
Eerola, H ;
Nevanlinna, H ;
Syrjäkoski, K ;
Kallioniemi, OP ;
Thompson, D ;
Evans, C ;
Peto, J ;
Lalloo, F ;
Evans, DG ;
Easton, DF .
JOURNAL OF MEDICAL GENETICS, 2005, 42 (07) :602-603
[2]   Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations:: A decision analysis [J].
Armstrong, K ;
Schwartz, JS ;
Randall, T ;
Rubin, SC ;
Weber, B .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1045-1054
[3]   Preference values for visual states in patients planning to undergo cataract surgery [J].
Bass, EB ;
Wills, S ;
Scott, IU ;
Javitt, JC ;
Tielsch, JM ;
Schein, OD ;
Steinberg, EP .
MEDICAL DECISION MAKING, 1997, 17 (03) :324-330
[4]   THE MARKOV PROCESS IN MEDICAL PROGNOSIS [J].
BECK, JR ;
PAUKER, SG .
MEDICAL DECISION MAKING, 1983, 3 (04) :419-458
[5]  
Brown ML, 2002, MED CARE, V40, P104
[6]   Recommendations for follow-up care of individuals with an inherited predisposition to cancer .1. Hereditary nonpolyposis colon cancer [J].
Burke, W ;
Petersen, G ;
Lynch, P ;
Botkin, J ;
Daly, M ;
Garber, J ;
Kahn, MJE ;
McTiernan, A ;
Offit, K ;
Thomson, E ;
Varricchio, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (11) :915-919
[7]   THE CLINICAL COURSE OF PULMONARY-EMBOLISM [J].
CARSON, JL ;
KELLEY, MA ;
DUFF, A ;
WEG, JG ;
FULKERSON, WJ ;
PALEVSKY, HI ;
SCHWARTZ, JS ;
THOMPSON, BT ;
POPOVICH, J ;
HOBBINS, TE ;
SPERA, MA ;
ALAVI, A ;
TERRIN, ML .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 326 (19) :1240-1245
[8]   The influence of familial and hereditary factors on the prognosis of breast cancer [J].
Chappuis, PO ;
Rosenblatt, J ;
Foulkes, WD .
ANNALS OF ONCOLOGY, 1999, 10 (10) :1163-1170
[9]   Re:: Population-based study of BRCA1 and BRCA2 mutations in 1035 unselected Finnish breast cancer patients [J].
Chappuis, PO ;
Hamel, N ;
Paradis, AJ ;
Deschênes, J ;
Tonin, PN ;
Ghadirian, P ;
Foulkes, WD .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (02) :152-153
[10]   Endometrioid carcinoma of the uterine corpus: A review of its pathology with emphasis on recent advances and problematic aspects [J].
Clement, PB ;
Young, TH .
ADVANCES IN ANATOMIC PATHOLOGY, 2002, 9 (03) :145-184